"Hep 3B2.1-7人肝癌復(fù)蘇細(xì)胞保種中心|帶STR證書

傳代比例：1:2-1:4(首次傳代建議1:2)

生長(zhǎng)特性：貼壁生長(zhǎng)

細(xì)胞傳代培養(yǎng)實(shí)驗(yàn)：體外培養(yǎng)的原代細(xì)胞或細(xì)胞株要在體外持續(xù)地培養(yǎng)就必須傳代，以便獲得穩(wěn)定的細(xì)胞株或得到大量的同種細(xì)胞，并維持細(xì)胞種的延續(xù)。培養(yǎng)的細(xì)胞形成單層匯合以后，由于密度過(guò)大生存空間不足而引起營(yíng)養(yǎng)枯竭，將培養(yǎng)的細(xì)胞分散，從容器中取出，以１:２或１:３以上的比率轉(zhuǎn)移到另外的容器中進(jìn)行培養(yǎng)，即為傳代培養(yǎng)；細(xì)胞“一代”指從細(xì)胞接種到分離再培養(yǎng)的一段期間，與細(xì)胞世代或倍增不同。在一代中，細(xì)胞培增３～６次。細(xì)胞傳代后，一般經(jīng)過(guò)三個(gè)階段：游離期、指數(shù)增生期和停止期。常用細(xì)胞分裂指數(shù)表示細(xì)胞增殖的旺盛程度，即細(xì)胞群的分裂相數(shù)/１００個(gè)細(xì)胞。一般細(xì)胞分裂指數(shù)介于０.２％～０.５％，腫瘤細(xì)胞可達(dá)３～５％；細(xì)胞接種２～３天分裂增殖旺盛，是活力ZuiHAO時(shí)期，稱指數(shù)增生期(對(duì)數(shù)生長(zhǎng)期)，適宜進(jìn)行各種試驗(yàn)。實(shí)驗(yàn)步驟：１.將長(zhǎng)成的培養(yǎng)細(xì)胞從二氧化碳培養(yǎng)箱中取出，在超凈工作臺(tái)中倒掉瓶?jī)?nèi)的培養(yǎng)，加入少許消化。(以面蓋住細(xì)胞為宜)，靜置５～１０分鐘。２.在倒置鏡下觀察被消化的細(xì)胞，如果細(xì)胞變圓，相互之間不再連接成片，這時(shí)應(yīng)立即在超凈臺(tái)中將消化倒掉，加入３～５ml新鮮培養(yǎng)，吹打，制成細(xì)胞懸。３.將細(xì)胞懸吸出２ml左右，加到另一個(gè)培養(yǎng)瓶中并向每個(gè)瓶中分別加３ml左右培養(yǎng)，蓋HAO瓶塞，送回二氧化碳培養(yǎng)箱中，繼續(xù)進(jìn)行培養(yǎng)。一般情況，傳代后的細(xì)胞在２小時(shí)左右就能附著在培養(yǎng)瓶壁上，２～４天就可在瓶?jī)?nèi)形成單層，需要再次進(jìn)行傳代。

換液周期：每周2-3次

P3J-HR-1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：每２-３天換液;生長(zhǎng)特性：懸浮生長(zhǎng) ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：HFF1細(xì)胞、HIEC6細(xì)胞、MCF7-GFP細(xì)胞

MOLP-8 Cells;背景說(shuō)明：漿細(xì)胞骨髓瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：Hs 742.T細(xì)胞、HSC-4細(xì)胞、SNU475細(xì)胞

NPC-TW01 Cells;背景說(shuō)明：鼻咽癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：Pfeiffer細(xì)胞、H1770細(xì)胞、C57/B6-L細(xì)胞

Hep 3B2.1-7人肝癌復(fù)蘇細(xì)胞保種中心|帶STR證書

背景信息：是一種人肝癌細(xì)胞系，是來(lái)自8歲男性黑人的組織。Hep 3B2.1-7細(xì)胞的染色體模式數(shù)目為60，在裸鼠中能致瘤。Hep 3B2.1-7細(xì)胞整合了完整的乙型肝炎病毒基因組。

細(xì)胞系的選擇需要考慮到細(xì)胞系的功能特點(diǎn)、生長(zhǎng)速率、鋪板效率、生長(zhǎng)條件和生長(zhǎng)特征、克隆效率、培養(yǎng)方式等因素，如果您想高產(chǎn)量表達(dá)重組蛋白，您可以選擇可以懸浮生長(zhǎng)的快速生長(zhǎng)細(xì)胞系。細(xì)胞培養(yǎng)的操作步驟主要包括傳代、換液、凍存和復(fù)蘇。這些步驟確保了細(xì)胞能夠在實(shí)驗(yàn)室環(huán)境中長(zhǎng)期存活并繼續(xù)增殖。傳代是將細(xì)胞從一個(gè)容器轉(zhuǎn)移到另一個(gè)容器的過(guò)程，以擴(kuò)大細(xì)胞數(shù)量；換液是為了清除代謝廢物并補(bǔ)充新鮮培養(yǎng)基；凍存則是為了長(zhǎng)期保存細(xì)胞，而復(fù)蘇則是重新激活冷凍保存的細(xì)胞使其恢復(fù)正常生長(zhǎng)。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來(lái)源說(shuō)明：細(xì)胞主要來(lái)源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫(kù)

COLO 201 Cells;背景說(shuō)明：該細(xì)胞源自一位７０歲白人男性，CSAp (CSAp-)和CEA陰性。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮+貼壁;形態(tài)特性：淋巴細(xì)胞;相關(guān)產(chǎn)品有：Madin Darby Canine Kidney細(xì)胞、HuP-T3細(xì)胞、Bovine Turbinate細(xì)胞

PC 61.5.3 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：alpha TC1 clone 6細(xì)胞、SK-MEL-MeWo細(xì)胞、U-251-MG細(xì)胞

H920 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：HG2855細(xì)胞、SPCA-1細(xì)胞、MA-c細(xì)胞

DanG Cells;背景說(shuō)明：胰腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：207細(xì)胞、TGW細(xì)胞、T2(174 x CEM.T2)細(xì)胞

Hep 3B2.1-7人肝癌復(fù)蘇細(xì)胞保種中心|帶STR證書

物種來(lái)源：人源、鼠源等其它物種來(lái)源

形態(tài)特性：上皮細(xì)胞樣

細(xì)胞凍存知識(shí)普及：細(xì)胞凍存是細(xì)胞保存的主要方法之一。利用凍存技術(shù)將細(xì)胞置于-１９６℃中低溫保存，可以使細(xì)胞暫時(shí)脫離生長(zhǎng)狀態(tài)而將其細(xì)胞性保存起來(lái)，這樣在需要的時(shí)候再?gòu)?fù)蘇細(xì)胞用于實(shí)驗(yàn)。而且適度地保存一定量的細(xì)胞，可以防止因正在培養(yǎng)的細(xì)胞被污染或其他意外事件而使細(xì)胞丟種，起到了細(xì)胞保種的作用。除此之外，還可以利用細(xì)胞凍存的形式來(lái)購(gòu)買、寄贈(zèng)、交換和運(yùn)送某些細(xì)胞。細(xì)胞凍存時(shí)向培養(yǎng)基中加入保護(hù)劑--終濃度５%.１５%的甘油或二甲基亞砜(DMSO)，可使溶冰點(diǎn)降低，加之在緩慢凍結(jié)條件下，細(xì)胞內(nèi)水分透出，減少了冰晶形成，從而避免細(xì)胞損傷。 采用""慢凍快融""的方法能較HAO地保證細(xì)胞存活。標(biāo)準(zhǔn)冷凍速度開(kāi)始為-１到-２℃/min，當(dāng)溫度低于-２５℃時(shí)可加速，到-８０℃之后可直接投入內(nèi)(-１９６℃)。

NR8383 Cells;背景說(shuō)明：NR８３８３(正常大鼠，１９８３年８月３日)來(lái)源于肺灌洗時(shí)的正常大鼠肺泡巨噬細(xì)胞。細(xì)胞在gerbil肺細(xì)胞連續(xù)培養(yǎng)液存在下培養(yǎng)了大約８-９個(gè)月。隨后，不再需要外源生長(zhǎng)因子。通過(guò)有限稀釋法從單個(gè)細(xì)胞克隆并亞克隆NR８３８３細(xì)胞，并三次用軟瓊脂亞克隆。細(xì)胞表現(xiàn)出巨噬細(xì)胞的特性，吞噬酵母多糖和銅綠，非特異性脂酶活性，F(xiàn)c受體，氧化降解；分泌IL-１,TNFbeta和IL-６，可重復(fù)地響應(yīng)外源生長(zhǎng)因子。NR８３８３細(xì)胞響應(yīng)博萊霉素，分泌TGFbeta前體。在博萊霉素刺激下，TGFbe;傳代方法：１：２傳代;生長(zhǎng)特性：半貼壁生長(zhǎng);形態(tài)特性：巨噬細(xì)胞;相關(guān)產(chǎn)品有：HAPI細(xì)胞、WM 451-Lu細(xì)胞、HEK293細(xì)胞

C17.2 Cells;背景說(shuō)明：神經(jīng)干細(xì)胞；C５７BL/６ x CD-１;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：U 138 MG細(xì)胞、Eca109細(xì)胞、U266S細(xì)胞

HEK293FT Cells;背景說(shuō)明：該細(xì)胞穩(wěn)定表達(dá)SV４０大T抗原，并且促進(jìn)最適病毒產(chǎn)物的產(chǎn)生。;傳代方法：１：２傳代;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：圓形;相關(guān)產(chǎn)品有：U-87-MG細(xì)胞、251MG細(xì)胞、B16F10細(xì)胞

CATHa Cells;背景說(shuō)明：神經(jīng)；SV４０轉(zhuǎn)化；C５７BL/６ x DBA/２;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：KMB17細(xì)胞、GM 637細(xì)胞、GM 637細(xì)胞

NS20-Y Cells;背景說(shuō)明：神經(jīng)母細(xì)胞瘤；雄性；A/J;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：F442-A細(xì)胞、HeLa229細(xì)胞、FM-88細(xì)胞

MCAEC Cells;背景說(shuō)明：冠狀動(dòng)脈內(nèi)皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：GM15452細(xì)胞、293T細(xì)胞、McA-RH 7777細(xì)胞

H-7721 Cells;背景說(shuō)明：用Northernblot方法，未能檢測(cè)到細(xì)胞中１.３kbLFIRE-１/HFREP-１mRNA的表達(dá)。;傳代方法：１：３傳代，２-３天換液一次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：TSU-Pr1細(xì)胞、TGBC-11-TKB細(xì)胞、HEp-2細(xì)胞

LN 382 Cells;背景說(shuō)明：膠質(zhì)瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：SK-N-FI細(xì)胞、T98G細(xì)胞、HuNS1細(xì)胞

RPMI8402 Cells;背景說(shuō)明：急性T淋巴細(xì)胞白血?。慌?傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：C-33 A細(xì)胞、MDCC MSB1細(xì)胞、Rat 1細(xì)胞

RPMI 7951 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，２天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：X63.Ag8.653細(xì)胞、BEAS 2B細(xì)胞、SU-DHL-4細(xì)胞

HRCEC Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：Calu3細(xì)胞、McArdle RH-7777細(xì)胞、OCI-Ly 10細(xì)胞

RPMI no 8226 Cells;背景說(shuō)明：來(lái)源于一位６１歲的男性漿細(xì)胞瘤患者；可產(chǎn)生免疫球蛋白輕鏈，未檢測(cè)到重鏈。;傳代方法：按１：２傳代，５-６小時(shí)可以看到細(xì)胞分裂;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：NCIH82細(xì)胞、KYSE-450細(xì)胞、ARH77細(xì)胞

CCRFCEM Cells;背景說(shuō)明：G.E. Foley 等人建立了類淋巴母細(xì)胞細(xì)胞株CCRF-CEM。 細(xì)胞是１９６４年１１月從一位四歲白人女性急性淋巴細(xì)胞白血病患者的外周血白血球衣中得到。此細(xì)胞系從香港收集而來(lái)。;傳代方法：１：２傳代。３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：MM-1S細(xì)胞、SR786細(xì)胞、HTori:3細(xì)胞

COLO824 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：U87MG細(xì)胞、G422細(xì)胞、H146細(xì)胞

NCIH1838 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：４傳代；每周換液２次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：High Five細(xì)胞、A-20細(xì)胞、RMS 1598細(xì)胞

Mel526 Cells;背景說(shuō)明：黑色素瘤;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：LC-MS細(xì)胞、KCL-22細(xì)胞、KRC/Y細(xì)胞

UACC 812 Cells;背景說(shuō)明：該細(xì)胞是由Liebovitz A等于１９８６年從一名４３歲的白人女性乳腺導(dǎo)管癌患者的乳腺切除腫瘤組織中分離建立的；手術(shù)前該病人曾接受過(guò)廣泛的化療。該細(xì)胞HER-２/neu癌基因序列有１５倍的擴(kuò)增；雌激素受體ER、孕激素受體PR和糖蛋白P陰性。;傳代方法：１：３傳代；５-７天１次。　;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：RL-952細(xì)胞、VMM5細(xì)胞、Tu212細(xì)胞

Hep 3B2.1-7人肝癌復(fù)蘇細(xì)胞保種中心|帶STR證書

1328-8139 Cells(提供STR鑒定圖譜)

Abcam HeLa EIF4EBP1 KO Cells(提供STR鑒定圖譜)

AG20116 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRF118 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XG302 Cells(提供STR鑒定圖譜)

C0131 Cells(提供STR鑒定圖譜)

CW11120 Cells(提供STR鑒定圖譜)

EC-MZ-2 Cells(提供STR鑒定圖譜)

GM05023 Cells(提供STR鑒定圖譜)

RTE Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３傳代，３-４天換液一次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：多角;相關(guān)產(chǎn)品有：ECC-1細(xì)胞、UACC 893細(xì)胞、H-250細(xì)胞

Melan-a Cells;背景說(shuō)明：黑色素細(xì)胞；自發(fā)永生；C５７BL/６;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：HCC15細(xì)胞、HNE1細(xì)胞、HPAF-2細(xì)胞

Neuro-2a Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代；２-３天換液１次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：HBSMC細(xì)胞、IOSE80細(xì)胞、Madin Darby Bovine Kidney細(xì)胞

KALS1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：多邊形;相關(guān)產(chǎn)品有：NCIH209細(xì)胞、2BS細(xì)胞、Cloudman S91 melanoma細(xì)胞

NRK clone 49F Cells;背景說(shuō)明：腎；成纖維細(xì)胞；自發(fā)永生;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：H322T細(xì)胞、OVCA-420細(xì)胞、OE21細(xì)胞

MIA Paca2 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代；;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：HUT-28細(xì)胞、rRTEC細(xì)胞、BL2141細(xì)胞

9.4 Cells(提供STR鑒定圖譜)

b.End3 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：Calu 6細(xì)胞、C1498細(xì)胞、8305-C細(xì)胞

CHP 126 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：H-23細(xì)胞、OVCAR.3細(xì)胞、Cates-1B細(xì)胞

TE671 Cells;背景說(shuō)明：胚胎性橫紋肌肉瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：AU-Mel細(xì)胞、SK.MEL.28細(xì)胞、Y3.AG.1.2.3細(xì)胞

LuCL4 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：CD 18細(xì)胞、BC-025細(xì)胞、Baby Hamster Kidney 21細(xì)胞

C3H/10T1/2 CL8 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：MT4細(xì)胞、NUGC3細(xì)胞、MCF.10A細(xì)胞

NCI-H865 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：SU-DHL-6細(xì)胞、AZ-521細(xì)胞、SU-DHL-2細(xì)胞

TCC Sup Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代，２-３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：Hs 695.T細(xì)胞、OCI-Ly01細(xì)胞、OCILY10細(xì)胞

R1800[RA] Cells;背景說(shuō)明：星形膠質(zhì) Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：EFM-192A細(xì)胞、NCI H716細(xì)胞、NCI-SNU-398細(xì)胞

GMA32 Cells(提供STR鑒定圖譜)

HAP1 PIM1 (-) 3 Cells(提供STR鑒定圖譜)

A2780CP70 Cells;背景說(shuō)明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：P3 NS1 Ag4/1細(xì)胞、THLE2細(xì)胞、B16 melanoma細(xì)胞

Tregs Cells;背景說(shuō)明：調(diào)節(jié)性T Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：Epstein-Barr-3細(xì)胞、SCC9細(xì)胞、SKNBE2細(xì)胞

Raji Cells;背景說(shuō)明：Raji細(xì)胞由PulvertaftRJV于１９６３年從一位１１歲黑人男孩的左上頜骨的Burkitt淋巴瘤中分離建立的，是第一個(gè)人類造血系統(tǒng)的連續(xù)傳代細(xì)胞，為B細(xì)胞起源。該細(xì)胞中含有EBV，需要在二級(jí)生物安全柜中操作；可作轉(zhuǎn)染宿主。;傳代方法：維持細(xì)胞濃度在４×１０５/ml-３×１０６/ml；根據(jù)細(xì)胞濃度每２-３天補(bǔ)液１次。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：VAESBJ細(xì)胞、Hs737T細(xì)胞、HGC-27細(xì)胞

BDCM Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：每周２-３次。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：OCI/AML2細(xì)胞、Plaepi 34細(xì)胞、SUIT-2細(xì)胞

DoHH2 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：VMRCRCZ細(xì)胞、KYSE 180細(xì)胞、H-2291細(xì)胞

COV-362 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：BAEC細(xì)胞、MKN45細(xì)胞、PLB 985細(xì)胞

TCC-PAN2 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：Suzhou Human Glioma-44細(xì)胞、LMH細(xì)胞、IOSE-Van細(xì)胞

SuDHL 8 Cells;背景說(shuō)明：彌漫大B淋巴瘤；腹腔積液轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：ACC-M細(xì)胞、Duck embryo細(xì)胞、SK-MEL-28細(xì)胞

HSP-239 Cells(提供STR鑒定圖譜)

KP-4-4 Cells(提供STR鑒定圖譜)

MoOV-51 Cells(提供STR鑒定圖譜)

NYSCF-10005-686-686-Skin-mR-iPSC Cells(提供STR鑒定圖譜)

RGS-3A Cells(提供STR鑒定圖譜)

Ubigene RAW 264.7 Cgas KO Cells(提供STR鑒定圖譜)

Yub634 Cells(提供STR鑒定圖譜)

HCC420 Cells(提供STR鑒定圖譜)

CL 1-0 Cells;背景說(shuō)明：肺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：HFT-8810細(xì)胞、U373-MG細(xì)胞、NCI-H292細(xì)胞

SF-763 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：CCRF SB細(xì)胞、RH8994細(xì)胞、L cell line細(xì)胞

NCI-H2066 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：聚團(tuán)懸浮;相關(guān)產(chǎn)品有：Panc_08_13細(xì)胞、Hs606T細(xì)胞、3T3細(xì)胞

H1092 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：隨細(xì)胞的密度而增加;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：MM134細(xì)胞、C166細(xì)胞、MCF/Adr細(xì)胞

CAMA1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：４傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞貼壁斑塊；緊湊，很少匯合;相關(guān)產(chǎn)品有：HL-7702細(xì)胞、MX-1細(xì)胞、2V6.11細(xì)胞

CAMA1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：４傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞貼壁斑塊；緊湊，很少匯合;相關(guān)產(chǎn)品有：HL-7702細(xì)胞、MX-1細(xì)胞、2V6.11細(xì)胞

CL-34 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：MDA134細(xì)胞、IOSE-29細(xì)胞、Hep 3B細(xì)胞

GM16136 Cells;背景說(shuō)明：肺；自發(fā)永生；雄性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：RGM1細(xì)胞、MUS-M1細(xì)胞、C3H10T1-2細(xì)胞

Lilly Laboratories Cell-Porcine Kidney 1 Cells;背景說(shuō)明：腎；自發(fā)永生；Hampshire;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：LIM 1215細(xì)胞、HMC-1細(xì)胞、HuH28細(xì)胞

MRC-V Cells;背景說(shuō)明：MRC-５細(xì)胞系來(lái)自１４周齡男性胎兒的正常肺組織，該細(xì)胞老化前能傳代４２~４６個(gè)倍增時(shí)間。;傳代方法：１：２-１：５傳代；每周１-２次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：Human Pancreatic Duct Epithelial細(xì)胞、HSC 3細(xì)胞、HO8910細(xì)胞

Caov-4 Cells;背景說(shuō)明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：IR983F細(xì)胞、Cor L51細(xì)胞、SW13細(xì)胞

Capan1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，２-３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：SK-RC-20細(xì)胞、UWB1-289細(xì)胞、HRMC細(xì)胞

SCC-9 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Ls-174-T細(xì)胞、TU 686細(xì)胞、A2780/CP70細(xì)胞

H292 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：８?jìng)鞔?；?３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：SNU620細(xì)胞、BALB/3T3 clone A31細(xì)胞、NCI-H157細(xì)胞

Hs 746.T Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：SK_N_BE2C細(xì)胞、U87 MG細(xì)胞、Pt K2 (NBL-5)細(xì)胞

SUP-B2 Cells(提供STR鑒定圖譜)

CCRF/CEM-C7 Cells;背景說(shuō)明：急性T淋巴細(xì)胞白血??；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：SLMT-1細(xì)胞、COLO206細(xì)胞、SCCVII/St細(xì)胞

RPPVEC Cells;背景說(shuō)明：肺靜脈；血管內(nèi)皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：H209細(xì)胞、HCT FET細(xì)胞、UACC893細(xì)胞

IOSE-80 Cells;背景說(shuō)明：卵巢；上皮細(xì)胞；SV４０轉(zhuǎn)化；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：mouse Inner Medullary Collecting Duct-3細(xì)胞、LO2細(xì)胞、H1781細(xì)胞

SW1990 Cells;背景說(shuō)明：胰腺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：SNU1040細(xì)胞、CACO2細(xì)胞、C-4I細(xì)胞

MM1 Cells;背景說(shuō)明：急性單核細(xì)胞白血病；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：MV 4;11細(xì)胞、Tregs細(xì)胞、NIH-3T3細(xì)胞

CL-11 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：University of Michigan-Urothelial Carcinoma-1細(xì)胞、MGH-U3 (RN)細(xì)胞、RC13細(xì)胞

HN13 Cells;背景說(shuō)明：舌鱗癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：16-HBEo細(xì)胞、B16 F10細(xì)胞、R 1610細(xì)胞

E.L.4 Cells;背景說(shuō)明：EL４是從用９,１０-二甲基-１,２-并蒽在C５７BL小鼠中誘導(dǎo)的淋巴瘤中建立的。 能抗０.１ mM 化可的松，對(duì)２０ mcg/ml PHA敏感。 還有一個(gè)亞株(EL４.IL-２, ATCC TIB-１８１)可以生成高水平的IL-２。 檢測(cè)表明肢骨發(fā)育畸形病毒(鼠痘)陰性。;傳代方法：１：２傳代;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：HEL9217細(xì)胞、HEL299細(xì)胞、SVHUC細(xì)胞

HTori-3 Cells;背景說(shuō)明：甲狀腺；SV４０轉(zhuǎn)化；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：LM6細(xì)胞、Hs 746T細(xì)胞、MUG-Chor1細(xì)胞

DMS-114 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代；每周換液２次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：MDAMB-231細(xì)胞、3396細(xì)胞、Panc_02_03細(xì)胞

RCK-8 Cells;背景說(shuō)明：彌漫大B淋巴瘤；腹腔轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：University of Arizona Cell Culture-893細(xì)胞、NCIH727細(xì)胞、GM-3573細(xì)胞

UO-31 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代；２-３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Human Kidney-2細(xì)胞、GM637A細(xì)胞、LM8細(xì)胞

RL-65 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：MD Anderson-Metastatic Breast-415細(xì)胞、SKG IIIa細(xì)胞、TEV-1細(xì)胞

ACC2 Cells;背景說(shuō)明：涎腺腺樣囊性癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有：Evsa-T細(xì)胞、Mouse podocyte細(xì)胞、CPA47細(xì)胞

Hep 3B2.1-7人肝癌復(fù)蘇細(xì)胞保種中心|帶STR證書

BayGenomics ES cell line CSH473 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRY563 Cells(提供STR鑒定圖譜)

Bhas42 Cells(提供STR鑒定圖譜)

KRIX-1 Cells(提供STR鑒定圖譜)

PEAA-3B5 Cells(提供STR鑒定圖譜)

PC12-G11 Cells(提供STR鑒定圖譜)

" "PubMed=6288577; DOI=10.1002/ijc.2910300106

Simon D., Aden D.P., Knowles B.B.

Chromosomes of human hepatoma cell lines.

Int. J. Cancer 30:27-33(1982)

Patent=US4393133

Knowles B.B., Aden D.P.

Human hepatoma derived cell line, process for preparation thereof, and uses therefor.

Patent number US4393133, 12-Jul-1983

PubMed=3023526; DOI=10.1099/0022-1317-67-11-2315

Aspinall S., Alexander J.J., Bos P.

Comparative expression of hepatitis B virus antigens in several cell model systems.

J. Gen. Virol. 67:2315-2323(1986)

DOI=10.1007/978-4-431-68349-0_4

Alexander J.J.

Human hepatoma cell lines.

(In book chapter) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo; Japan (1987)

PubMed=2439335; DOI=10.1111/j.1432-1033.1987.tb11497.x

Vincent C., Marceau M., Blangarin P., Bouic P., Madjar J.-J., Revillard J.-P.

Purification of alpha 1-microglobulin produced by human hepatoma cell lines. Biochemical characterization and comparison with alpha 1-microglobulin synthesized by human hepatocytes.

Eur. J. Biochem. 165:699-704(1987)

PubMed=3431441; DOI=10.1016/s0076-6879(87)51006-0

Darlington G.J.

Liver cell lines.

Methods Enzymol. 151:19-38(1987)

PubMed=8224613; DOI=10.1096/fasebj.7.14.8224613

Puisieux A., Galvin K., Troalen F., Bressac B., Marcais C., Galun E., Ponchel F., Yakicier C., Ji J.-W., Ozturk M.

Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines.

FASEB J. 7:1407-1413(1993)

PubMed=8389256; DOI=10.1093/carcin/14.5.987

Hsu I.-C., Tokiwa T., Bennett W.P., Metcalf R.A., Welsh J.A., Sun T.-T., Harris C.C.

p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.

Carcinogenesis 14:987-992(1993)

PubMed=7972006; DOI=10.1073/pnas.91.23.11045; PMCID=PMC45163

Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P., Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H., Harris C.C.

Mutations and altered expression of p16INK4 in human cancer.

Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994)

PubMed=8050184; DOI=10.1111/j.1365-2249.1994.tb06089.x; PMCID=PMC1534706

Wadee A.A., Paterson A., Coplan K.A., Reddy S.G.

HLA expression in hepatocellular carcinoma cell lines.

Clin. Exp. Immunol. 97:328-333(1994)

PubMed=8835345; DOI=10.1002/(SICI)1096-9071(199602)48:2<133::aid-jmv3>3.0.CO;2-A

Tsuboi S., Nagamori S., Miyazaki M., Mihara K., Fukaya K.-i., Teruya K., Kosaka T., Tsuji T., Namba M.

Persistence of hepatitis C virus RNA in established human hepatocellular carcinoma cell lines.

J. Med. Virol. 48:133-140(1996)

DOI=10.11418/jtca1981.16.3_173

Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-i., Ohashi R., Namba M.

The p53 gene status and other cellular characteristics of human cell lines maintained in our laboratory.

Tissue Cult. Res. Commun. 16:173-178(1997)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::aid-mc5>3.0.CO;2-D

Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Screening the p53 status of human cell lines using a yeast functional assay.

Mol. Carcinog. 19:243-253(1997)

PubMed=9359923; DOI=10.18926/AMO/30789

Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-i., Ishioka C., Namba M.

Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory.

Acta Med. Okayama 51:261-265(1997)

PubMed=10523694; DOI=10.3892/or.6.6.1267

Gao C., Ohashi R., Pu H., Inoue Y., Tsuji T., Miyazaki M., Namba M.

Yeast functional assay of the p53 gene status in 11 cell lines and 26 surgical specimens of human hepatocellular carcinoma.

Oncol. Rep. 6:1267-1271(1999)

PubMed=11050057; DOI=10.1053/jhep.2000.19349

Wong N., Lai P.B.-S., Pang E., Leung T.W.-T., Lau J.W.-Y., Johnson P.J.

A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping.

Hepatology 32:1060-1068(2000)

PubMed=12029633; DOI=10.1053/jhep.2002.33683

Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M., Inazawa J.

TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.

Hepatology 35:1476-1484(2002)

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234

Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.

Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.

Mol. Cancer Ther. 4:399-412(2005)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=20454443; DOI=10.1155/2010/904767; PMCID=PMC2861168

Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.

Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.

J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010)

PubMed=20937217; DOI=10.1170/149

Di Masi A., Viganotti M., Antoccia A., Magrelli A., Salvatore M., Azzalin G., Tosto F., Lorenzetti S., Maranghi F., Mantovani A., Macino G., Tanzarella C., Taruscio D.

Characterization of HuH6, Hep3B, HepG2 and HLE liver cancer cell lines by WNT/beta-catenin pathway, microRNA expression and protein expression profile.

Cell. Mol. Biol. 56:OL1299-OL1317(2010)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=23505090; DOI=10.1002/hep.26402

Wang K., Lim H.Y., Shi S., Lee J., Deng S.-B., Xie T., Zhu Z., Wang Y.-L., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.-C.

Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.

Hepatology 58:706-717(2013)

PubMed=23887712; DOI=10.1038/ncomms3218; PMCID=PMC3731665

Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

Nat. Commun. 4:2218.1-2218.7(2013)

PubMed=24116068; DOI=10.1371/journal.pone.0075692; PMCID=PMC3792989

Weiskirchen R., Weimer J., Meurer S.K., Kron A., Seipel B., Vater I., Arnold N., Siebert R., Xu L.-M., Friedman S.L., Bergmann C.

Genetic characteristics of the human hepatic stellate cell line LX-2.

PLoS ONE 8:E75692-E75692(2013)

PubMed=25574106; DOI=10.3748/wjg.v21.i1.311; PMCID=PMC4284350

Cevik D., Yildiz G., Ozturk M.

Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.

World J. Gastroenterol. 21:311-317(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=29610054; DOI=10.1016/j.dmpk.2018.03.003; PMCID=PMC6309175

Shi J., Wang X.-W., Lyu L.-Y., Jiang H., Zhu H.-J.

Comparison of protein expression between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics: Focusing on drug-metabolizing enzymes.

Drug Metab. Pharmacokinet. 33:133-140(2018)

PubMed=30629668; DOI=10.1371/journal.pone.0210404; PMCID=PMC6328144

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

Screening human cell lines for viral infections applying RNA-Seq data analysis.

PLoS ONE 14:E0210404-E0210404(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001

Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S., Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N., Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P., Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.

Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.

Gastroenterology 157:760-776(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001; PMCID=PMC7505724

Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J., Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y., Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J., Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H., Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X., Hui L.-J.

A pharmacogenomic landscape in human liver cancers.

Cancer Cell 36:179-193.e11(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2; PMCID=PMC6687785

Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

Nat. Commun. 10:3574.1-3574.11(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254

Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.

Quantitative proteomics of the Cancer Cell Line Encyclopedia.

Cell 180:387-402.e16(2020)"